Clinical trial / 2010
Breast tissue Ki-67 was lower after secoisolariciresinol diglycoside supplementation in high-risk women.
In a single-arm trial, 45 premenopausal women at high risk for breast cancer received 50 mg daily of secoisolariciresinol diglycoside for 12 months. Ki-67 decreased from a median of 4% to 2% in 36 participants (P < 0.001). Atypical cytology was also less prevalent after treatment (P = 0.035), alongside significant increases in median plasma enterolactone and total lignans.
- Study type
- Uncontrolled clinical trial
- Who was studied
- 45 premenopausal women at high risk for breast cancer
- What was measured
- Ki-67 expression and breast cancer risk biomarkers
THE PAPER
Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside.
Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Petroff BK, Khan QJ, Sharma P, Setchell KD, Zhao X, Phillips TA, Metheny T, Hughes JR, Yeh HW, Johnson KA. Cancer Prev Res (Phila), 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.